1083323-05-0

Basic information

• Product Name: 2,4-difluoro-N-{5-[3-(1-methyl-1H-pyrazol-4-yl)-6-quinoxalinyl]-3-pyridinyl}benzenesulfonamide
• Synonyms: 2,4-difluoro-N-{5-[3-(1-methyl-1H-pyrazol-4-yl)-6-quinoxalinyl]-3-pyridinyl}benzenesulfonamide
• CAS NO: 1083323-05-0
• Molecular Weight: 478.482
• Mol File: 1083323-05-0.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 2,4-difluoro-N-{5-[3-(1-methyl-1H-pyrazol-4-yl)-6-quinoxalinyl]-3-pyridinyl}benzenesulfonamide(CAS DataBase Reference)
• NIST Chemistry Reference: 2,4-difluoro-N-{5-[3-(1-methyl-1H-pyrazol-4-yl)-6-quinoxalinyl]-3-pyridinyl}benzenesulfonamide(1083323-05-0)
• EPA Substance Registry System: 2,4-difluoro-N-{5-[3-(1-methyl-1H-pyrazol-4-yl)-6-quinoxalinyl]-3-pyridinyl}benzenesulfonamide(1083323-05-0)

Safety Data

• Hazardous Substances Data: 1083323-05-0(Hazardous Substances Data)

Upstream product

• 1083326-23-1 N-(5-bromo-3-pyridinyl)-2,4-difluorobenzenesulfonamide 
• 1083325-88-5 2-(1-methyl-1H-pyrazol-4-yl)-7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)quinoxaline 

Relevant articles and documents

QUINOXALINE DERIVATIVES AS PI3 KINASE INHIBITORS

Invented is a method of inhibiting the activity/function of PI3 kinases using quinoxaline derivatives. Also invented is a method of treating one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries by the administration of quinoxaline derivatives.